Human_JJ Immunodeficiency_NN Virus_NP Type_NP 1_CD Genotypic_JJ and_CC Pharmacokinetic_JJ Determinants_NNS of_IN the_DT Virological_NP Response_NP to_TO Lopinavir-Ritonavir-Containing_NP Therapy_NN in_IN Protease_NP Inhibitor-Experienced_NP Patients_NPS The_DT response_NN to_TO regimens_NNS including_VBG lopinavir-ritonavir_NN (_( LPV/r_NP )_) in_IN patients_NNS who_WP have_VBP received_VBN multiple_JJ protease_NN (_( PR_NP )_) inhibitors_NNS (_( PI_NP )_) can_MD be_VB analyzed_VBN in_IN terms_NNS of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NP )_) genotypic_JJ and_CC pharmacokinetic_JJ (_( pK_NN )_) determinants_NNS ._SENT We_PP studied_VBD these_DT factors_NNS and_CC the_DT evolution_NN of_IN HIV-1_JJ resistance_NN in_IN response_NN to_TO LPV/r_NP in_IN a_DT prospective_JJ study_NN of_IN patients_NNS receiving_VBG LPV/r_NP under_IN a_DT temporary_JJ authorization_NN in_IN Bordeaux_NP ,_, France_NP ._SENT HIV-1_NP PR_NP and_CC reverse_JJ transcriptase_NN sequences_NNS were_VBD determined_VBN at_IN baseline_JJ LPV/r_NP for_IN all_PDT the_DT patients_NNS and_CC at_IN month_NN 3_CD (_( M3_NP )_) and_CC M6_NP in_IN the_DT absence_NN of_IN response_NN to_TO treatment_NN ._SENT pK_NN measurements_NNS were_VBD determined_VBN at_IN M1_NP and_CC M3_NP ._SENT Virological_JJ failure_NN (_( VF_NP )_) was_VBD defined_VBN as_IN a_DT plasma_NN viral_JJ load_NN >=400_NN copies/ml_NN at_IN M3_NP ._SENT A_DT multivariate_JJ analysis_NN of_IN the_DT predictors_NNS of_IN VF_NP ,_, including_VBG clinical_JJ and_CC biological_JJ characteristics_NNS and_CC the_DT treatment_NN history_NN of_IN the_DT patients_NNS ,_, was_VBD performed_VBN ._SENT The_DT PR_NP gene_NN sequence_NN at_IN M0_NP ,_, including_VBG individual_JJ mutations_NNS or_CC a_DT previously_RB defined_VBN LPV_NP mutation_NN score_NN (_( D._NP J._NP Kempf_NP ,_, J._NP D._NP Isaacson_NP ,_, M._NP S._NP King_NP ,_, S._NP C._NP Brun_NP ,_, Y._NP Xu_NP ,_, K._NP Real_NP ,_, B._NP M._NP Bernstein_NP ,_, A._NP J._NP Japour_NP ,_, E._NP Sun_NP ,_, and_CC R._NP A._NP Rode_NP ,_, J._NP Virol_NP ._SENT 75:7262-7269_CD ,_, 2001_CD )_) ,_, and_CC the_DT individual_JJ exposure_NN to_TO LPV_NP were_VBD also_RB included_VBN covariates_NNS ._SENT Sixty-eight_NP patients_NNS were_VBD enrolled_VBN ._SENT Thirty-four_NP percent_NN had_VBD a_DT virological_JJ response_NN at_IN M3_NP ._SENT An_DT LPV_NP mutation_NN score_NN of_IN >5_JJ mutations_NNS ,_, the_DT presence_NN of_IN the_DT PR_NP I54V_NP mutation_NN at_IN baseline_NN ,_, a_DT high_JJ number_NN of_IN previous_JJ PIs_NP ,_, prior_JJ therapy_NN with_IN ritonavir_NN or_CC indinavir_NN ,_, absence_NN of_IN coprescription_NN of_IN efavirenz_NP ,_, and_CC a_DT lower_JJR exposure_NN to_TO LPV_NP or_CC lower_JJR LPV_NP trough_NN concentrations_NNS were_VBD independently_RB associated_VBN with_IN VF_NP on_IN LPV/r_NP ._SENT Additional_JJ PI_NP resistance_NN mutations_NNS ,_, including_VBG primary_JJ mutation_NN I50V_NP ,_, could_MD be_VB selected_VBN in_IN patients_NNS failing_VBG on_IN LPV/r_NP ._SENT Genotypic_JJ and_CC pK_NN parameters_NNS should_MD be_VB used_VBN to_TO optimize_VB the_DT virological_JJ response_NN to_TO LPV/r_NP in_IN PI-experienced_JJ patients_NNS and_CC to_TO avoid_VB further_RBR viral_JJ evolution_NN ._SENT Treatment_NN of_IN human_JJ immunodeficiency_NN virus_NN (HIV)-infected_VBD individuals_NNS with_IN combination_NN therapy_NN including_VBG protease_NN inhibitors_NNS (_( PI_NP )_) results_NNS in_IN a_DT significant_JJ suppression_NN of_IN HIV_NP replication_NN and_CC in_IN improvement_NN in_IN clinical_JJ outcomes_NNS ,_, with_IN marked_JJ reductions_NNS in_IN HIV-associated_JJ morbidity_NN and_CC mortality_NN ._SENT However_RB ,_, the_DT efficacy_NN of_IN antiretroviral_NP (_( ARV_NP )_) treatment_NN can_MD be_VB impaired_VBN by_IN several_JJ factors_NNS ,_, including_VBG poor_JJ compliance_NN with_IN treatment_NN regimens_NNS ,_, suboptimal_JJ antiviral_JJ potency_NN and_CC drug_NN concentrations_NNS ,_, and_CC selection_NN of_IN ARV-resistant_NP HIV_NP quasispecies_NNS ._SENT Resistance_NN to_TO PI_NP is_VBZ driven_VBN by_IN the_DT selection_NN of_IN primary_JJ mutations_NNS located_VBN close_RB to_TO the_DT active_JJ site_NN of_IN the_DT HIV_NP type_NN 1_CD (_( HIV-1_NP )_) protease_NN ,_, producing_VBG significant_JJ changes_NNS in_IN the_DT affinity_NN of_IN the_DT binding_NN of_IN the_DT inhibitor_NN to_TO the_DT mutant_JJ active_JJ site_NN and_CC often_RB occurs_VBZ early_RB during_IN virological_JJ rebound_NN ._SENT Secondary_JJ resistance_NN mutations_NNS may_MD be_VB selected_VBN later_RBR and_CC may_MD compensate_VB for_IN the_DT initial_JJ decrease_NN of_IN viral_JJ fitness_NN related_VBN to_TO the_DT appearance_NN of_IN primary_JJ mutations_NNS ._SENT These_DT secondary_JJ mutations_NNS tend_VBP to_TO be_VB common_JJ to_TO all_DT PI_NP ,_, facilitating_VBG the_DT emergence_NN of_IN resistance_NN to_TO the_DT whole_JJ PI_NP class_NN ._SENT Lopinavir_NP (LPV)-ritonavir_NP (_( LPV/r_NP )_) is_VBZ a_DT coformulation_NN of_IN lopinavir_NN ,_, an_DT HIV_NP PI_NP ,_, and_CC low-dose_NN ritonavir_NN ,_, which_WDT inhibits_VBZ LPV_NP metabolism_NN and_CC which_WDT enhances_VBZ plasma_NN LPV_NP levels_NNS ._SENT LPV/r_NP has_VBZ shown_VBN significant_JJ potency_NN in_IN treatment-naive_JJ and_CC in_IN PI-experienced_JJ patients_NNS ._SENT Few_JJ data_NNS concerning_VBG the_DT determinants_NNS and_CC the_DT emergence_NN of_IN drug_NN resistance_NN in_IN LPV/r-treated_JJ patients_NNS are_VBP available_JJ ._SENT In_IN the_DT LPV/r_NP arm_NN of_IN a_DT first-line_NN ARV_NP therapy_NN protocol_NN ,_, all_DT virological_JJ failures_NNS (_( VF_NP )_) were_VBD shown_VBN to_TO correspond_VB to_TO rebounds_NNS with_IN wild-type_NP HIV-1_NP (_( B._NP Bernstein_NP ,_, J._NP Moseley_NP ,_, D._NP Kempf_NP ,_, M._NP King_NP ,_, K._NP Gu_NP ,_, E._NP Bauer_NP ,_, and_CC E._NP Sun_NP ,_, Abstr_NP ._SENT 8th_JJ Conf_NP ._SENT Retrovir_NP ._SENT Opportunistic_JJ Infect_NNS ._SENT ,_, abstr_NN ._SENT 453_CD ,_, 2001_CD )_) ._SENT A_DT panel_NN of_IN viral_JJ isolates_NNS from_IN patients_NNS failing_VBG therapy_NN with_IN other_JJ PI_NP were_VBD used_VBN to_TO show_VB that_IN 11_CD amino_NN acid_NN mutations_NNS in_IN the_DT protease_NN were_VBD associated_VBN with_IN a_DT reduced_VBN sensitivity_NN to_TO LPV_NP ._SENT The_DT number_NN of_IN baseline_JJ mutations_NNS out_IN of_IN the_DT cumulative_JJ number_NN of_IN these_DT mutations_NNS (_( LPV_NP mutation_NN score_NN )_) was_VBD shown_VBN to_TO be_VB predictive_JJ of_IN the_DT virological_JJ response_NN to_TO a_DT regimen_NN including_VBG LPV/r_NP in_IN PI-experienced_NP ,_, nonnucleoside_JJ HIV-1_JJ reverse_JJ transcriptase_NN inhibitor_NN (NNRTI)-naive_JJ patients_NNS (_( D._NP Kempf_NP ,_, S._NP Brun_NP ,_, R._NP Rode_NP ,_, J._NP Isaacson_NP ,_, M._NP King_NP ,_, Y._NP Xu_NP ,_, K._NP Real_NP ,_, A._NP Hsu_NP ,_, R._NP Granneman_NP ,_, Y._NP Lie_NP ,_, N._NP Hellmann_NP ,_, B._NP Bernstein_NP ,_, and_CC E._NP Sun_NP ,_, 4th_JJ Int_NP ._SENT Workshop_NN HIV_NP Drug_NP Resist_NP ._SENT Treatment_NP Strategies_NP ,_, 12_CD to_TO 16_CD June_NP 2000_CD ,_, Sitges_NP ,_, Spain_NP ,_, abstr_NP ._SENT 89_CD ,_, 2000_CD )_) ._SENT In_IN this_DT study_NN ,_, the_DT overall_JJ virological_JJ response_NN was_VBD important_JJ ,_, since_IN efavirenz_NN (_( a_DT NNRTI_NP )_) was_VBD systematically_RB coadministered_JJ ,_, enhancing_VBG the_DT efficacy_NN of_IN the_DT ARV_NP therapy_NN ._SENT We_PP thought_VBD it_PP important_JJ to_TO precisely_RB identify_VB the_DT virological_JJ and_CC pharmacological_JJ determinants_NNS of_IN the_DT virological_JJ response_NN to_TO LPV/r-containing_NP regimens_NNS in_IN the_DT context_NN of_IN a_DT salvage_NN therapy_NN in_IN multiple-PI-experienced_JJ ,_, frequently_RB NNRTI-experienced_JJ patients_NNS ._SENT Study_NN design_NN ._SENT |_SYM From_IN May_NP to_TO November_NP 2000_CD ,_, patients_NNS followed_VBD up_RP at_IN the_DT Bordeaux_NP University_NP Hospital_NP by_IN the_DT Aquitaine_NP Cohort_NP of_IN the_DT Groupe_NP d'Epidemiologie_NP Clinique_NP du_FW SIDA_NP en_FW Aquitaine_NP and_CC receiving_VBG LPV/r_NP in_IN the_DT setting_NN of_IN the_DT French_JJ Drug_NP Agency_NP temporary_JJ authorization_NN for_IN use_NN (_( ATU_NP )_) were_VBD prospectively_RB enrolled_VBN into_IN this_DT study_NN ._SENT Patients_NNS were_VBD PI_NP experienced_VBN ,_, and_CC there_EX were_VBD strict_JJ ATU_NP entrance_NN criteria_NNS (_( CD4_NP cells_NNS <_200/mul 4_CD )_) when_WRB enrollment_NN began_VBD ,_, with_IN a_DT progressive_JJ enlargement_NN to_TO authorize_VB the_DT use_NN of_IN LPV/r_NP in_IN a_DT larger_JJR PI-experienced_JJ population_NN ._SENT At_IN baseline_NN of_IN LPV/r_NP therapy_NN (_( month_NN 0_CD [_SYM M0_NP ]_SYM )_) demographic_JJ data_NNS ,_, prior_JJ and_CC current_JJ ARV_NP regimens_NNS ,_, HIV-1_NP RNA_NP ,_, and_CC CD4+_NP cell_NN count_NN were_VBD collected_VBN ,_, as_RB well_RB as_IN HIV-1_JJ protease_NN and_CC reverse_JJ transcriptase_NN (_( RT_NP )_) gene_NN sequences_NNS ._SENT In_IN two_CD patients_NNS ,_, on_IN treatment_NN interruption_NN at_IN M0_NP ,_, preinterruption_NN parameters_NNS measured_VBD 2_CD (_( for_IN one_CD patient_NN )_) and_CC 3_CD months_NNS (_( for_IN the_DT other_JJ )_) before_IN beginning_VBG LPV/r_NP were_VBD considered_VBN for_IN the_DT analysis_NN ._SENT Patients_NNS were_VBD followed_VBN up_RP at_IN M1_NP ,_, M3_NP ,_, and_CC M6_NP with_IN viral_JJ load_NN and_CC CD4_NN measurements_NNS and_CC additional_JJ HIV-1_JJ genotype_NN determination_NN in_IN case_NN of_IN VF_NP ,_, defined_VBN as_IN plasma_NN HIV-1_NP RNA_NP level_NN of_IN >=400_JJ copies/ml_NN ._SENT Virological_JJ analyses_NNS ._SENT |_SYM Plasma_NP HIV-1_NP RNA_NP was_VBD quantitated_VBN using_VBG the_DT bDNA_NP Quantiplex_NP assay_NN ,_, version_NN 3.0_CD (_( Chiron_NP Bayer_NP ,_, Emeryville_NP ,_, Calif._NP )_) ._SENT The_DT RT_NP and_CC protease_NN gene_NN sequences_NNS were_VBD determined_VBN from_IN plasma_NN samples_NNS by_IN the_DT Agence_NP Nationale_NP de_NP Recherches_NP sur_NP le_FW SIDA_NP (_( ANRS_NP ;_: Paris_NP ,_, France_NP )_) consensus_NN method_NN with_IN a_DT CEQ_NP L_NP sequencer_NN (_( Beckman_NP Coulter_NP )_) as_IN previously_RB described_VBN ._SENT All_DT individual_JJ ARV_NP resistance_NN mutations_NNS reported_VBD by_IN the_DT International_NP AIDS_NP Society-USA_NP (_( IAS-USA_NP )_) panel_NN were_VBD considered_VBN ._SENT For_IN each_DT patient_NN at_IN baseline_JJ LPV/r_NP an_DT LPV_NP mutation_NN score_NN was_VBD defined_VBN as_IN the_DT number_NN of_IN protease_NN mutations_NNS out_RP of_IN the_DT following_VBG 11_CD mutations_NNS :_: L10F/I/R/V_NP ,_, K20M/R_NP ,_, L24I_NP ,_, M46I/L_NP ,_, F53L_NP ,_, I54L/T/V_NP ,_, L63P_NP ,_, A71I/L/V/T_NP ,_, V82A/F/T_NP ,_, I84V_NP ,_, and_CC L90M_NP ._SENT The_DT virology_NN laboratory_NN of_IN Bordeaux_NP participates_VBZ to_TO the_DT ANRS_JJ quality_NN control_NN assessment_NN of_IN HIV-1_JJ drug_NN resistance_NN sequencing_NP (_( F._NP Brun-Vezinet_NP ,_, D._NP Descamps_NP ,_, V._NP Calvez_NP ,_, M._NP L._NP Chaix_NP ,_, J._NP Izopet_NP ,_, B._NP Masquelier_NP ,_, A._NP Ruffault_NP ,_, C._NP Tamalet_NP ,_, P._NP Dehertogh_NP ,_, C._NP Loveday_NP ,_, L._NP Perrin_NP ,_, D._NP Costagliola_NP ,_, and_CC The_DT ANRS_NP Resistance_NP Group_NP ,_, 5th_JJ Int_NP ._SENT Workshop_NN HIV_NP Drug_NP Resist_NP ._SENT Treatment_NP Strategies_NP ,_, 4_CD to_TO 8_CD June_NP 2001_CD ,_, Scottsdale_NP ,_, Ariz._NP ,_, abstr_NP ._SENT 157_CD ,_, 2001_CD )_) ._SENT Pharmacokinetic_JJ analysis_NN ._SENT (_( i_NP )_) Data_NP preparation_NN and_CC pharmacokinetic_JJ analysis_NN ._SENT |_SYM Patient_NP data_NNS files_NNS were_VBD created_VBN from_IN observed_JJ data_NNS for_IN LPV_NP plasma_NN concentrations_NNS by_IN using_VBG the_DT PASTRX_NP program_NN in_IN USC*PACK_NP PC_NP clinical_JJ programs_NNS (_( R._NP Jelliffe_NP ,_, University_NP of_IN Southern_NP California_NP ,_, Los_NP Angeles_NP ,_, Calif._NP )_) ._SENT Clinical_JJ ,_, pharmacokinetic_JJ ,_, and_CC demographic_JJ data_NNS and_CC treatment_NN history_NN relevant_JJ to_TO the_DT pharmacokinetic_JJ analysis_NN were_VBD obtained_VBN ._SENT At_IN entry_NN and_CC each_DT follow-up_NN visit_NN ,_, the_DT patient_NN filled_VBN in_IN a_DT questionnaire_NN seeking_VBG information_NN on_IN the_DT dates_NNS ,_, times_NNS ,_, and_CC doses_NNS of_IN nucleoside_NN RT_NP inhibitors_NNS (_( NRTI_NP )_) and_CC PI_NP taken_VBN and_CC recent_JJ over-the-counter_JJ medication_NN used_VBD ._SENT Each_DT individual_NN provided_VBD one_CD blood_NN sample_NN per_IN visit_NN :_: a_DT predose_JJ trough_NN sample_NN (_( for_IN trough_NN LPV_NP plasma_NN concentration_NN [_SYM Cmin_NP ]_SYM )_) or_CC a_DT postdose_JJ sample_NN (_( maximum_JJ concentration_NN of_IN the_DT drug_NN in_IN plasma_NN [_SYM Cmax_NP ]_SYM )_) collected_VBN between_IN 2_CD and_CC 5_CD h_NN after_IN the_DT dose_NN taken_VBN during_IN the_DT visit_NN ._SENT Blood_NN samples_NNS for_IN the_DT pharmacokinetic_JJ study_NN were_VBD drawn_VBN at_IN M1_NP (_( steady_JJ state_NN )_) and_CC then_RB at_IN M3_NP ._SENT For_IN the_DT analysis_NN of_IN possible_JJ relationships_NNS between_IN pharmacokinetic_JJ and_CC virologic_JJ parameters_NNS ,_, areas_NNS under_IN the_DT plasma_NN concentration-time_JJ curve_NN over_IN a_DT 12-h_NP dosing_VBG interval_NN (_( LPV_NP AUC0-12_NP )_) were_VBD used_VBN ,_, with_IN a_DT cutoff_NN value_NN defined_VBN as_IN the_DT median_JJ LPV_NP AUC0-12_NP obtained_VBD in_IN the_DT study_NN ._SENT (_( ii_NP )_) Plasma_NP sample_NN analysis_NN ._SENT |_SYM Plasma_NP LPV/r_NP concentrations_NNS were_VBD measured_VBN by_IN a_DT validated_VBN high-performance_JJ liquid_JJ chromatography_NN method_NN and_CC UV_NP detection_NN ._SENT The_DT lower_JJR and_CC upper_JJ limits_NNS of_IN LPV_NP quantification_NN were_VBD 0.05_CD and_CC 50_CD mg/liter_NN ,_, respectively_RB ._SENT For_IN that_DT study_NN ,_, assay_NN correlation_NN coefficients_NNS (_( 20_CD analytical_JJ runs_NNS )_) exceeded_VBD 0.998_CD for_IN LPV_NP ._SENT Based_VBN on_IN quality_NN control_NN samples_NNS ,_, interday_NN accuracy_NN for_IN the_DT two_CD analytes_NNS ranged_VBN from_IN 99_CD to_TO 101_CD %_NN of_IN a_DT known_VBN concentration_NN and_CC interday_NN variability_NN was_VBD <8%._In =400_JJ copies_NNS of_IN plasma_NN HIV-1_NP RNA/ml_NP )_) with_IN a_DT P_NN value_NN of_IN <0.25_NN in_IN the_DT univariate_JJ analysis_NN were_VBD included_VBN in_IN multivariate_JJ models_NNS by_IN using_VBG a_DT descending_VBG stepwise_JJ logistic_JJ regression_NN ._SENT The_DT variables_NNS significant_JJ at_IN the_DT 0.05_CD level_NN were_VBD kept_VBN in_IN the_DT final_JJ models_NNS to_TO study_VB first_RB the_DT significance_NN of_IN the_DT LPV_NP mutation_NN score_NN and_CC then_RB the_DT significance_NN of_IN individual_JJ protease_NN mutations_NNS and_CC pharmacokinetic_JJ parameters_NNS for_IN the_DT virological_JJ response_NN ._SENT Four_CD different_JJ models_NNS were_VBD used_VBN because_IN of_IN the_DT colinearity_NN between_IN the_DT LPV_NP mutation_NN score_NN and_CC individual_JJ mutations_NNS and_CC the_DT lower_JJR number_NN of_IN patients_NNS with_IN pharmacokinetic_JJ measurements_NNS ._SENT Analyses_NNS were_VBD performed_VBN using_VBG Stata_NP (_( College_NP Station_NP ,_, Tex._NP )_) statistical_JJ software_NN ._SENT Baseline_JJ characteristics_NNS ._SENT |_SYM Sixty-eight_NP patients_NNS were_VBD included_VBN in_IN the_DT study_NN ._SENT Their_PP$ biological_JJ and_CC clinical_JJ characteristics_NNS are_VBP described_VBN in_IN Table_NP ._SENT Most_JJS of_IN the_DT patients_NNS were_VBD multiple-PI_NP and_CC NNRTI_NP experienced_VBD ,_, with_IN a_DT high_JJ viral_JJ load_NN at_IN baseline_NN ._SENT The_DT HIV-1_JJ genotypes_NNS for_IN 66_CD patients_NNS were_VBD obtained_VBN ,_, the_DT other_JJ two_CD patients_NNS having_VBG a_DT viral_JJ load_NN below_IN 500_CD copies/ml_NN at_IN baseline_NN ._SENT The_DT prevalence_NN figures_NNS of_IN baseline_JJ protease_NN resistance_NN mutations_NNS ,_, as_RB reported_VBN by_IN the_DT IAS-USA_NP panel_NN are_VBP summarized_VBN in_IN Fig._NN in_IN the_DT format_NN of_IN categories_NNS of_IN the_DT LPV_NP mutation_NN score_NN ._SENT The_DT mean_JJ (_( +-_JJ standard_JJ deviation_NN [_SYM SD_NP ]_SYM )_) number_NN of_IN protease_NN resistance_NN mutations_NNS was_VBD 7_CD +-_NN 3_CD (_( median_NN ,_, 7_CD ;_: range_NN ,_, 1_CD to_TO 19_CD )_) ,_, the_DT mean_JJ LPV_NP score_NN was_VBD 5_CD +-_NN 2_CD (_( median_NN ,_, 5_CD ;_: range_NN ,_, 1_CD to_TO 9_CD )_) ._SENT The_DT RT_NP gene_NN sequences_NNS for_IN 65_CD patients_NNS were_VBD determined_VBN ;_: the_DT prevalences_NNS of_IN the_DT baseline_JJ RT_NP resistance_NN mutations_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT The_DT mean_JJ number_NN of_IN NRTI_NP resistance_NN mutations_NNS was_VBD 5_CD +-_NN 2_CD (_( median_NN ,_, 5_CD ;_: range_NN ,_, 0_CD to_TO 9_CD )_) ,_, and_CC the_DT mean_JJ number_NN of_IN nucleoside-associated_JJ mutations_NNS (_( NAMS_NP ;_: formerly_RB zidovudine_NP resistance_NN mutations_NNS ;_: M41L_NP ,_, D67N_NP ,_, K70R_NP ,_, L210W_NP ,_, T215Y/F_NP ,_, and_CC K219Q/E_NP )_) was_VBD 3_CD +-_NN 1_CD (_( median_NN ,_, 3_CD ;_: range_NN ,_, 0_CD to_TO 5_CD )_) ._SENT Ten_CD patients_NNS had_VBD no_DT NNRTI_NP resistance_NN mutation_NN ._SENT Description_NN of_IN the_DT LPV/r-containing_NP regimens_NNS and_CC virological_JJ and_CC immunological_JJ responses_NNS ._SENT |_SYM The_DT NRTI_NP combined_VBN with_IN LPV/r_NP were_VBD zidovudine_NP ,_, didanosine_NN ,_, zalcitabine_NN ,_, lamivudine_NP ,_, stavudine_NP ,_, and_CC abacavir_NN in_IN 5_CD (_( 7_CD %_NN )_) ,_, 45_CD (_( 67_CD %_NN )_) ,_, 7_CD (_( 10_CD %_NN )_) ,_, 32_CD (_( 48_CD %_NN )_) ,_, 28_CD (_( 42_CD %_NN )_) ,_, and_CC 18_CD (_( 27_CD %_NN )_) of_IN the_DT 68_CD patients_NNS ,_, respectively_RB ._SENT Nevirapine_NP and_CC efavirenz_NP were_VBD prescribed_VBN in_IN eight_CD (_( 12_CD %_NN )_) and_CC seven_CD (_( 10_CD %_NN )_) patients_NNS ,_, respectively_RB ._SENT LPV/r-containing_NN regimens_NNS associated_VBN three_CD drugs_NNS in_IN 53_CD patients_NNS ,_, four_CD drugs_NNS in_IN 13_CD patients_NNS ,_, and_CC five_CD drugs_NNS in_IN 2_CD patients_NNS ._SENT The_DT patients_NNS exhibited_VBD a_DT median_JJ decrease_NN of_IN plasma_NN HIV-1_NP RNA_NP of_IN 1.16_CD (_( 0.40_CD to_TO 2.37_CD )_) log10_NN copies/ml_NN at_IN M3_NP (_( n_NN =_SYM 62_CD )_) and_CC of_IN 0.90_CD (_( 0.42_CD to_TO 1.80_CD )_) log10_NN copies/ml_NN at_IN M6_NP (_( n_NN =_SYM 63_CD )_) and_CC mean_VB increases_NNS of_IN 64_CD (_( range_NN ,_, 35_CD to_TO 107_CD )_) CD4+_NP cells/mul_NP at_IN M3_NP (_( n_NN =_SYM 48_CD )_) and_CC of_IN 81_CD (_( range_NN ,_, 34_CD to_TO 140_CD )_) CD4+_NP cells/mul_NP at_IN M6_NP (_( n_NN =_SYM 35_CD )_) ._SENT The_DT proportion_NN of_IN patients_NNS with_IN a_DT plasma_NN HIV-1_NP RNA_NP below_IN 400_CD copies/ml_NN was_VBD 34_CD %_NN at_IN M3_NP (_( n_NN =_SYM 65_CD )_) and_CC 28_CD %_NN at_IN M6_NP (_( n_NN =_SYM 61_CD )_) ._SENT With_IN a_DT less_RBR strict_JJ definition_NN (_( plasma_NN HIV-1_NP RNA_NP of_IN <400_copies/ml =1_JJ log10_NN copy/ml_NN )_) ,_, the_DT proportion_NN of_IN virological_JJ response_NN reached_VBD 55_CD %_NN at_IN M3_NP and_CC 46_CD %_NN at_IN M6_NP ._SENT Between_IN M0_NP and_CC M3_NP ,_, four_CD patients_NNS stopped_VBN LPV/r_NP therapy_NN and_CC one_CD died_VBN of_IN an_DT AIDS-related_JJ syndrome_NN ._SENT Two_CD patients_NNS stopped_VBD LPV/r_NP between_IN M3_NP and_CC M6_NP ._SENT Pharmacokinetic_JJ results_NNS ._SENT |_SYM Sixty-eight_NP patients_NNS were_VBD included_VBN in_IN this_DT pharmacokinetic_JJ study_NN ._SENT At_IN pharmacokinetic_JJ steady_JJ state_NN ,_, the_DT mean_JJ LPV_NP plasma_NN concentrations_NNS and_CC times_NNS to_TO reach_VB these_DT concentrations_NNS at_IN M1_NP and_CC M3_NP ,_, respectively_RB ,_, were_VBD as_RB follows_VBZ :_: Cmin_NP ,_, 3.88_CD +-_NN 1.97_CD and_CC 4.22_CD +-_NN 2.66_CD mg/liter_NN ;_: Tmin_NP (_( time_NN to_TO reach_VB LPV_NP Cmin_NP )_) ,_, 12.19_CD +-_NN 2.56_CD and_CC 12.49_CD +-_NN 1.99_CD h_NN ;_: Cmax_NP ,_, 9.79_CD +-_NN 5.09_CD and_CC 9.10_CD +-_NN 5.09_CD mg/liter_NN ;_: Tmax_NP (_( time_NN to_TO reach_VB LPV_NP Cmax_NP )_) ,_, 3.26_CD +-_NN 1.42_CD and_CC 2.29_CD +-_NN 0.68_CD h._NN The_DT LPV_NP exposures_NNS determined_VBN from_IN the_DT individual_JJ AUC0-12_NN were_VBD 87_CD +-_NN 21_CD and_CC 77_CD +-_NN 53_CD mg/liter_NN h_NN at_IN M1_NP and_CC M3_NP ,_, respectively_RB ._SENT The_DT median_JJ LPV_NP AUC0-12_NP in_IN the_DT whole_JJ study_NN was_VBD at_IN 80_CD mg/liter_NN h_NN and_CC defined_VBD the_DT cutoff_NN value_NN for_IN comparisons_NNS ._SENT The_DT mean_NN calculated_VBN Cmin_NP values_NNS at_IN M1_NP and_CC M3_NP were_VBD 3.37_CD +-_NN 0.86_CD and_CC 2.93_CD +-_NN 0.80_CD mg/liter_NN ,_, respectively_RB ._SENT Determinants_NNS of_IN the_DT response_NN to_TO LPV/r_NP ._SENT |_SYM The_DT univariate_JJ analysis_NN showed_VBD that_IN the_DT following_VBG were_VBD associated_VBN with_IN a_DT poor_JJ virological_JJ response_NN (_( P_NN <_0.250): 5_CD ;_: a_DT large_JJ total_JJ number_NN of_IN protease_NN mutations_NNS ;_: a_DT low_JJ LPV_NP AUC0-12_NP ;_: a_DT low_JJ LPV_NP Cmin_NP at_IN M1_NP and_CC M3_NP ;_: prior_JJ exposure_NN to_TO didanosine_NN ,_, abacavir_NP ,_, nevirapine_NN ,_, ritonavir_NP ,_, indinavir_NN ,_, or_CC amprenavir_NN ;_: a_DT high_JJ number_NN of_IN previous_JJ PI_NP ,_, a_DT high_JJ number_NN of_IN treatment_NN lines_NNS ;_: and_CC prior_JJ exposure_NN to_TO NNRTI_NP ._SENT On_IN the_DT other_JJ hand_NN ,_, the_DT coprescription_NN of_IN efavirenz_NP ,_, the_DT presence_NN of_IN baseline_JJ protease_NN mutation_NN V77I_NP ,_, D30N_NP ,_, or_CC N88D_NP ,_, an_DT older_JJR age_NN at_IN inclusion_NN ,_, and_CC the_DT female_JJ gender_NN were_VBD associated_VBN with_IN a_DT better_RBR virological_JJ response_NN ._SENT The_DT characteristics_NNS of_IN the_DT RT_NP gene_NN sequence_NN (_( total_JJ number_NN of_IN NRTI_NP and_CC NNRTI_NP mutations_NNS ,_, number_NN of_IN NAMS_NP )_) were_VBD not_RB associated_VBN with_IN the_DT virological_JJ outcome_NN at_IN M3_NP ._SENT The_DT median_JJ LPV_NP AUC0-12_NP values_NNS at_IN M1_NP in_IN patients_NNS with_IN virological_JJ response_NN and_CC in_IN patients_NNS with_IN VF_NP were_VBD 104_CD (_( interquartile_JJ range_NN [_SYM IQR_NP ]_SYM ,_, 97_CD to_TO 114_CD )_) and_CC 79_CD (_( IQR_NP ,_, 67_CD to_TO 90_CD )_) mg/liter_NN h_NN ,_, respectively_RB (_( P_NN <_SYM 0.0001_CD )_) ._SENT The_DT median_JJ LPV_NP Cmin_NP values_NNS at_IN M1_NP in_IN patients_NNS with_IN virological_JJ response_NN and_CC in_IN patients_NNS with_IN VF_NP were_VBD 4.01_CD (_( IQR_NP ,_, 3.76_CD to_TO 4.23_CD )_) and_CC 3.08_CD (_( IQR_NP ,_, 2.65_CD to_TO 3.81_CD )_) mg/liter_NN ,_, respectively_RB (_( P_NN <_SYM 0.0001_CD )_) ._SENT The_DT results_NNS of_IN the_DT multivariate_JJ analysis_NN of_IN the_DT determinants_NNS of_IN the_DT virological_JJ response_NN ,_, according_VBG to_TO four_CD different_JJ models_NNS ,_, are_VBP shown_VBN in_IN Table_NP ._SENT In_IN the_DT first_JJ model_NN ,_, a_DT higher_JJR number_NN of_IN prior_JJ PI_NP ,_, prior_JJ therapy_NN with_IN at_IN least_JJS one_CD NNRTI_NP ,_, and_CC an_DT LPV_NP mutation_NN score_NN higher_JJR than_IN 5_CD were_VBD associated_VBN with_IN VF_NP ;_: on_IN the_DT other_JJ hand_NN ,_, the_DT female_JJ gender_NN and_CC the_DT presence_NN of_IN efavirenz_NN within_IN the_DT LPV/r-including_NP regimen_NN were_VBD associated_VBN with_IN a_DT better_RBR virological_JJ response_NN ._SENT Four_CD of_IN six_CD patients_NNS who_WP received_VBD efavirenz_NN with_IN LPV/r_NP had_VBD a_DT virological_JJ response_NN ,_, with_IN a_DT baseline_JJ NNRTI_NP resistance_NN genotype_NN encoding_VBG the_DT following_VBG mutational_JJ patterns_NNS :_: V106A_NP ,_, K101E_NP plus_CC Y181I_NP ,_, wild_JJ type_NN ,_, and_CC Y181C_NP plus_CC G190A_NP ._SENT The_DT other_JJ two_CD patients_NNS had_VBD VF_NP ,_, one_CD with_IN a_DT G190A_NP mutation_NN and_CC one_CD with_IN a_DT Y181C_NP at_IN baseline_NN ._SENT To_TO explain_VB the_DT protective_JJ effect_NN of_IN the_DT female_JJ gender_NN found_VBN in_IN our_PP$ analysis_NN ,_, we_PP compared_VBD the_DT different_JJ characteristics_NNS of_IN the_DT patients_NNS according_VBG to_TO gender_VB ._SENT No_DT statistically_RB significant_JJ difference_NN was_VBD observed_VBN ,_, but_CC the_DT median_JJ LPV_NP Cmin_NP at_IN M1_NP tended_VBD to_TO be_VB higher_JJR in_IN women_NNS than_IN in_IN men_NNS (_( 3.93_CD versus_IN 3.23_CD mg/liter_NN ;_: P_NN =_SYM 0.08_CD )_) ._SENT The_DT second_JJ model_NN was_VBD constructed_VBN to_TO evaluate_VB the_DT role_NN of_IN individual_JJ protease_NN mutations_NNS ._SENT The_DT presence_NN of_IN the_DT I54V_NP mutation_NN was_VBD independently_RB associated_VBN with_IN a_DT poor_JJ virological_JJ response_NN at_IN M3_NP ._SENT The_DT I77V_NP mutation_NN was_VBD associated_VBN with_IN a_DT better_RBR virological_JJ response_NN at_IN M3_NP ._SENT The_DT third_JJ model_NN included_VBD pharmacokinetic_JJ parameters_NNS and_CC the_DT detailed_JJ description_NN of_IN prior_JJ PI_NP use_NN ._SENT Prior_JJ treatment_NN with_IN ritonavir_NN or_CC indinavir_NN was_VBD associated_VBN with_IN a_DT worse_JJR response_NN ;_: a_DT higher_JJR LPV_NP AUC0-12_NP at_IN M1_NP was_VBD associated_VBN with_IN a_DT better_JJR response_NN ._SENT In_IN a_DT model_NN including_VBG the_DT number_NN of_IN prior_JJ PI_NP but_CC not_RB the_DT details_NNS of_IN the_DT prior_JJ PI_NP ,_, LPV_NP AUC0-12_NP was_VBD still_RB a_DT predictive_JJ factor_NN (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT fourth_JJ model_NN shows_VBZ that_IN higher_JJR calculated_JJ LPV_NP Cmin_NP at_IN M1_NP was_VBD also_RB associated_VBN with_IN a_DT better_JJR response_NN ._SENT The_DT LPV_NP mutation_NN score_NN remained_VBD predictive_JJ of_IN the_DT virological_JJ response_NN in_IN all_PDT the_DT multivariate_JJ models_NNS ._SENT The_DT virological_JJ response_NN according_VBG to_TO the_DT LPV_NP mutation_NN score_NN is_VBZ shown_VBN in_IN Fig._NN ,_, with_IN a_DT reduced_VBN response_NN in_IN the_DT patients_NNS with_IN six_CD or_CC more_JJR mutations_NNS ,_, particularly_RB using_VBG a_DT strict_JJ definition_NN of_IN the_DT virological_JJ response_NN ._SENT Evolution_NN of_IN the_DT protease_NN genotype_NN in_IN patients_NNS failing_VBG on_IN LPV/r_NP ._SENT |_SYM The_DT protease_NN gene_NN sequence_NN could_MD be_VB determined_VBN at_IN M3_NP and/or_CC M6_NP on_IN an_DT LPV/r-containing_NP regimen_NN for_IN 48_CD patients_NNS without_IN virological_JJ response_NN at_IN these_DT points_NNS of_IN follow-up_NN ._SENT We_PP determined_VBD the_DT variations_NNS for_IN any_DT amino_NN acid_NN between_IN baseline_NN and_CC M3_NP and_CC M6_NP ._SENT Fifteen_CD patients_NNS exhibited_VBD no_DT change_NN between_IN M0_NP and_CC M3_NP or_CC M6_NP ._SENT For_IN the_DT other_JJ 33_CD patients_NNS ,_, at_IN least_JJS one_CD residue_NN was_VBD changed_VBN ._SENT As_IN shown_VBN ,_, different_JJ PI_NP resistance_NN mutations_NNS appeared_VBD on_IN LPV/r_NP ,_, corresponding_VBG to_TO mutations_NNS included_VBN or_CC not_RB included_VBD in_IN the_DT LPV_NP mutation_NN score_NN ._SENT Interestingly_RB ,_, one_CD primary_JJ resistance_NN mutation_NN (_( I50V_NP )_) formerly_RB described_VBD to_TO be_VB associated_VBN with_IN resistance_NN to_TO amprenavir_NN ,_, was_VBD selected_VBN in_IN four_CD patients_NNS ,_, three_CD of_IN whom_WP had_VBD no_DT prior_JJ amprenavir_NN therapy_NN ._SENT Other_JJ changes_NNS were_VBD selected_VBN at_IN 13_CD different_JJ positions_NNS not_RB involved_VBN so_RB far_RB in_IN resistance_NN to_TO PI_NP ,_, with_IN low_JJ frequencies_NNS (_( one_CD or_CC two_CD patients_NNS for_IN each_DT amino_NN acid_NN )_) ;_: for_IN four_CD patients_NNS only_JJ changes_NNS within_IN these_DT 13_CD positions_NNS were_VBD detected_VBN ._SENT In_IN 38_CD patients_NNS without_IN virological_JJ response_NN at_IN M3_NP and_CC M6_NP and_CC with_IN a_DT calculated_JJ LPV_NP AUC0-12_NP at_IN M1_NP or_CC M3_NP ,_, the_DT viral_JJ evolution_NN in_IN the_DT protease_NN (_( with_IN at_IN least_JJS one_CD additional_JJ PI_NP resistance_NN mutation_NN at_IN M3_NP and/or_CC M6_NP )_) occurred_VBD in_IN 4_CD of_IN 12_CD (_( 33_CD %_NN )_) patients_NNS with_IN low_JJ (_( <80_JJ mg/liter_NN h_NN )_) LPV_NP AUC0-12_NP and_CC in_IN 22_CD of_IN 25_CD (_( 88_CD %_NN )_) patients_NNS with_IN correct_JJ or_CC high_JJ LPV_NP AUC0-12_NP (_( P_NN <_SYM 0.001_CD )_) ._SENT FIG._NN 1_CD ._SENT |_SYM (_( A_NP )_) Mutations_NNS in_IN the_DT HIV-1_JJ protease_NN in_IN 66_CD patients_NNS at_IN baseline_JJ therapy_NN with_IN LPV/r_NP ._SENT (_( A_NP )_) Mutations_NNS in_IN the_DT HIV-1_JJ protease_NN in_IN 66_CD patients_NNS at_IN baseline_JJ therapy_NN with_IN LPV/r_NP ._SENT Protease_NN mutations_NNS are_VBP those_DT reported_VBN by_IN the_DT IAS-USA_NP panel_NN ._SENT LPV_NP mutations_NNS ,_, mutations_NNS included_VBD in_IN the_DT LPV_NP mutation_NN score_NN ,_, i.e._FW ,_, the_DT number_NN of_IN baseline_JJ protease_NN mutations_NNS out_RB of_IN 11_CD possible_JJ mutations_NNS :_: L10F/I/R/V_NP ,_, K20M/R_NP ,_, L24I_NP ,_, M46I/L_NP ,_, F53L_NP ,_, I54L/T/V_NP ,_, L63P_NP ,_, A71I/L/V/T_NP ,_, V82A/F/T_NP ,_, I84V_NP ,_, and_CC L90_NP M_NP ;_: other_JJ R_NN mutations_NNS ,_, mutations_NNS not_RB included_VBD in_IN the_DT LPV_NP mutation_NN score_NN ;_: %_NN of_IN patients_NNS ,_, percentage_NN of_IN patients_NNS with_IN the_DT corresponding_JJ mutation_NN at_IN baseline_JJ LPV/r_NP ._SENT (_( B_LS )_) Mutations_NNS in_IN the_DT HIV-1_NP RT_NP in_IN 65_CD patients_NNS at_IN baseline_JJ LPV/r_NP ._SENT NRTI_NP and_CC NNRTI_NP resistance_NN mutations_NNS are_VBP those_DT reported_VBN by_IN the_DT IAS-USA_NP panel_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Virological_JJ response_NN to_TO LPV/r-containing_NP regimens_NNS at_IN M3_NP according_VBG to_TO the_DT LPV_NP mutation_NN score_NN (_( n_NN =_SYM 65_CD )_) ._SENT Virological_JJ response_NN to_TO LPV/r-containing_NP regimens_NNS at_IN M3_NP according_VBG to_TO the_DT LPV_NP mutation_NN score_NN (_( n_NN =_SYM 65_CD )_) ._SENT <400_JJ copies/ml_NN ,_, patients_NNS with_IN plasma_NN HIV-1_NP RNA_NP levels_NNS of_IN <400_JJ copies/ml_NN at_IN M3_NP ;_: <400_JJ c/ml_NN or_CC -1log10_NN ,_, patients_NNS with_IN plasma_NN HIV-1_NP RNA_NP levels_NNS of_IN <400_copies/ml 1_CD log10_NN unit_NN between_IN M0_NP and_CC M3_NP ;_: LPV_NP mutation_NN score_NN ,_, number_NN of_IN baseline_JJ protease_NN mutations_NNS out_RB of_IN 11_CD mutations_NNS :_: L10F/I/R/V_NP ,_, K20M/R_NP ,_, L24I_NP ,_, M46I/L_NP ,_, F53L_NP ,_, I54L/T/V_NP ,_, L63P_NP ,_, A71I/L/V/T_NP ,_, V82A/F/T_NP ,_, I84V_NP ,_, and_CC L90M_NP ._SENT TABLE_NN 1_CD |_SYM Clinical_JJ and_CC biological_JJ characteristics_NNS of_IN the_DT patients_NNS at_IN baseline_JJ LPV/r_NP therapy_NN ,_, Aquitaine_NP Cohort_NP ,_, 2000_CD to_TO 2001_CD TABLE_NP 2_CD |_SYM Multivariate_JJ analysis_NN of_IN the_DT factors_NNS associated_VBN with_IN VF_NP under_IN LPV/r_NP therapy_NN ,_, Aquitaine_NP Cohort_NP ,_, 2000_CD to_TO 2001_CD TABLE_NP 3_CD |_SYM Amino_NP acid_NN mutations_NNS selected_VBN in_IN the_DT HIV-1_JJ protease_NN in_IN 48_CD patients_NNS on_IN LPV/r-containing_NP regimens_NNS ,_, Aquitaine_NP Cohort_NP ,_, 2000_CD to_TO 2001_CD In_IN this_DT study_NN ,_, we_PP described_VBD the_DT determinants_NNS of_IN the_DT virological_JJ response_NN to_TO LPV/r-containing_NP regimens_NNS in_IN PI-experienced_JJ patients_NNS ._SENT The_DT response_NN to_TO therapy_NN in_IN our_PP$ study_NN ,_, using_VBG strict_JJ criteria_NNS (_( plasma_NN HIV-1_NP RNA_NP <_SYM 400_CD copies/ml_NN at_IN M3_NP )_) ,_, was_VBD lower_JJR than_IN in_IN the_DT initial_JJ study_NN (_( Kempf_NP et_FW al._FW ,_, 4th_JJ Int_NP ._SENT Workshop_NN HIV_NP Drug_NP Resist_NP ._SENT Treatment_NP Strategies_NP ,_, 2000_CD ,_, Sitges_NP ,_, Spain_NP ,_, abstr_NN ._SENT 89_LS )_) of_IN the_DT response_NN to_TO LPV/r_NP in_IN PI-experienced_JJ patients_NNS ._SENT This_DT could_MD be_VB explained_VBN by_IN the_DT characteristics_NNS of_IN our_PP$ population_NN :_: highly_RB pretreated_JJ and_CC NNRTI_NP and_CC multiple_JJ PI_NP experienced_VBD ,_, with_IN a_DT high_JJ number_NN of_IN PI_NP resistance_NN mutations_NNS at_IN baseline_NN ._SENT Nevertheless_RB ,_, the_DT previously_RB constructed_VBN LPV_NP mutation_NN score_NN was_VBD shown_VBN to_TO be_VB predictive_JJ of_IN the_DT virological_JJ response_NN in_IN our_PP$ multivariate_JJ analysis_NN ,_, with_IN a_DT higher_JJR risk_NN for_IN VF_NP with_IN a_DT score_NN at_IN six_CD or_CC more_JJR mutations_NNS ._SENT Similar_JJ data_NNS were_VBD obtained_VBN in_IN another_DT study_NN (_( V._NP Calvez_NP ,_, I._NP Cohen-Codar_NP ,_, A._NP G._NP Marcelin_NP ,_, E._NP Guillevic_NP ,_, J._NP Isaacson_NP ,_, R._NP Rode_NP ,_, B._NP Bernstein_NP ,_, E._NP Sun_NP ,_, D._NP Kempf_NP ,_, and_CC J._NP P._NP Chauvin_NP ,_, 5th_JJ Int_NP ._SENT Workshop_NN HIV_NP Drug_NP Resist_NP ._SENT Treatment_NP Strategies_NP ,_, 2001_CD ,_, Scottsdale_NP ,_, Ariz._NP ,_, abstr_NP ._SENT 82_CD ,_, 2001_CD )_) ,_, suggesting_VBG that_IN the_DT LPV_NP mutation_NN score_NN could_MD be_VB relevant_JJ for_IN optimizing_VBG the_DT use_NN of_IN LPV/r_NP in_IN salvage_NN therapy_NN ._SENT We_PP also_RB explored_VBD the_DT implication_NN of_IN specific_JJ mutations_NNS in_IN the_DT response_NN to_TO LPV/r_NP ._SENT The_DT presence_NN of_IN the_DT L54V_NP protease_NN mutation_NN at_IN baseline_NN was_VBD associated_VBN with_IN a_DT higher_JJR risk_NN of_IN VF_NP ._SENT Although_IN this_DT mutation_NN can_MD be_VB considered_VBN a_DT secondary_JJ PI_NP resistance_NN mutation_NN ,_, it_PP seems_VBZ to_TO play_VB an_DT important_JJ role_NN in_IN resistance_NN to_TO LPV_NP ._SENT In_IN a_DT study_NN using_VBG correlations_NNS between_IN reduced_VBN phenotypic_JJ sensitivity_NN to_TO LPV_NP and_CC the_DT protease_NN gene_NN sequences_NNS from_IN clinical_JJ isolates_NNS (_( P._NP R._NP Harrigan_NP ,_, C._NP Van_NP Den_NP Eynde_NP ,_, and_CC B._NP A._NP Larder_NP ,_, Scottsdale_NP workshop_NN ,_, abstr_NN ._SENT 49_CD ,_, 2001_CD )_) the_DT L54Vmutation_NN was_VBD associated_VBN with_IN the_DT highest_JJS decrease_NN in_IN susceptibility_NN to_TO LPV/r_NP ._SENT This_DT mutation_NN also_RB belonged_VBD to_TO the_DT mutations_NNS appearing_VBG on_IN LPV/r_NP in_IN the_DT followed-up_JJ patients_NNS without_IN optimal_JJ virological_JJ response_NN in_IN our_PP$ study_NN ._SENT These_DT findings_NNS are_VBP consistent_JJ with_IN the_DT hypothesis_NN that_IN the_DT addition_NN of_IN the_DT I54V_NP mutation_NN on_IN a_DT background_NN of_IN previously_RB established_VBN PI_NP mutations_NNS enables_VBZ the_DT virus_NN to_TO acquire_VB high-level_JJ resistance_NN to_TO LPV_NP without_IN impairing_VBG its_PP$ replication_NN capacity_NN ._SENT Our_PP$ finding_NN that_IN the_DT use_NN of_IN efavirenz_NP reduced_VBD the_DT risk_NN of_IN treatment_NN failure_NN has_VBZ to_TO be_VB interpreted_VBN with_IN regard_NN with_IN the_DT baseline_JJ pattern_NN of_IN NNRTI_NP resistance_NN mutations_NNS in_IN patients_NNS who_WP received_VBD efavirenz_NN and_CC had_VBD a_DT virological_JJ response_NN ._SENT The_DT absence_NN of_IN mutation_NN K103N_NP ,_, which_WDT is_VBZ frequently_RB found_VBN in_IN efavirenz-resistant_JJ isolates_NNS ,_, could_MD explain_VB a_DT residual_JJ activity_NN of_IN efavirenz_NP ._SENT A_DT potential_JJ interpretation_NN of_IN these_DT data_NNS ,_, despite_IN a_DT limited_JJ number_NN of_IN patients_NNS ,_, is_VBZ that_IN efavirenz_NP could_MD contribute_VB significantly_RB to_TO the_DT virologic_JJ success_NN of_IN a_DT regimen_NN ,_, even_RB in_IN NNRTI-experienced_JJ patients_NNS ,_, when_WRB administered_VBN as_IN part_NN of_IN a_DT sufficiently_RB potent_JJ regimen_NN ._SENT The_DT observed_JJ individual_JJ LPV_NP pharmacokinetic_JJ parameters_NNS such_JJ as_IN Cmin_NP ,_, Tmin_NP ,_, Cmax_NP ,_, and_CC Tmax_NP seemed_VBD to_TO be_VB stable_JJ when_WRB the_DT LPV_NP pharmacokinetic_NN was_VBD in_IN steady_JJ state_NN ._SENT This_DT observed_JJ stability_NN between_IN M1_NP and_CC M3_NP should_MD enable_VB us_PP in_IN the_DT future_NN to_TO monitor_VB individual_JJ LPV_NP plasma_NN concentrations_NNS and_CC to_TO adapt_VB LPV/r_NP dosages_NNS when_WRB necessary_JJ ._SENT All_PDT our_PP$ pharmacokinetic_JJ results_NNS were_VBD similar_JJ to_TO previously_RB reported_VBN data_NNS (_( R._NP Bertz_NP ,_, W._NP Lam_NP ,_, and_CC S._NP Brun_NP ,_, Abstr_NP ._SENT 39th_JJ Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NN ._SENT 327_CD ,_, 1999_CD )_) ._SENT However_RB ,_, the_DT Cmin_NP and_CC AUC0-12_NP levels_NNS found_VBD in_IN the_DT group_NN of_IN virological_JJ responders_NNS (_( about_RB 4_CD mg/ml_NN and_CC 100_CD mg/ml_NN h_NN ,_, respectively_RB )_) suggest_VBP that_IN higher_JJR LPV_NP concentrations_NNS than_IN previously_RB described_VBN in_IN first-line_NN drug-treated_JJ patients_NNS could_MD be_VB necessary_JJ to_TO be_VB active_JJ on_IN the_DT first-available-PI-resistant_JJ viruses_NNS ._SENT A_DT lower_JJR LPV_NP individual_JJ exposure_NN (_( AUC0-12_NP )_) ,_, as_RB well_RB as_IN lower_JJR LPV_NP trough_NN concentrations_NNS at_IN M1_NP ,_, were_VBD associated_VBN with_IN a_DT higher_JJR risk_NN of_IN VF_NP at_IN M3_NP ;_: interestingly_RB ,_, the_DT predictive_JJ value_NN of_IN the_DT baseline_JJ LPV_NP mutation_NN score_NN was_VBD strengthened_VBN in_IN the_DT multivariate_JJ models_NNS including_VBG the_DT pharmacokinetics_NN parameters_NNS ,_, suggesting_VBG that_IN both_DT genotypic_JJ and_CC pharmacokinetic_JJ follow-up_NN are_VBP of_IN interest_NN for_IN the_DT monitoring_NN of_IN LPV/r-containing_NP salvage_NN regimens_NNS ._SENT One_CD striking_JJ finding_NN was_VBD the_DT protective_JJ effect_NN of_IN the_DT female_JJ gender_NN found_VBN in_IN the_DT multivariate_JJ analysis_NN ._SENT The_DT higher_JJR LPV_NP Cmin_NP found_VBD in_IN women_NNS could_MD partially_RB explain_VB this_DT effect_NN ._SENT In_IN a_DT recent_JJ study_NN ,_, a_DT lower_JJR clearance_NN of_IN saquinavir_NN ,_, resulting_VBG in_IN an_DT higher_JJR exposure_NN to_TO this_DT drug_NN ,_, was_VBD found_VBN to_TO be_VB related_VBN to_TO the_DT female_JJ gender_NN (_( R._NP C._NP Brundage_NP ,_, E._NP Acosta_NP ,_, R._NP Aubrich_NP ,_, D._NP Katzenstein_NP ,_, R._NP Culick_NP ,_, and_CC C._NP V._NP Fletcher_NP ,_, Abstr_NP ._SENT 9th_JJ Conf_NP ._SENT Retrovir_NP ._SENT Opportunistic_JJ Infect_NNS ._SENT ,_, abstr_NN ._SENT 779_CD ,_, 2002_CD )_) ._SENT Although_IN no_DT data_NNS concerning_VBG the_DT adherence_NN to_TO therapy_NN ,_, a_DT putative_JJ confounding_VBG factor_NN ,_, were_VBD available_JJ in_IN our_PP$ study_NN ,_, a_DT similar_JJ difference_NN in_IN LPV_NP clearance_NN could_MD account_VB for_IN the_DT observed_JJ effect_NN of_IN the_DT female_JJ gender_NN ._SENT In_IN a_DT subset_NN of_IN patients_NNS with_IN uncontrolled_JJ plasma_NN HIV-1_NP RNA_NP on_IN LPV/r_NP ,_, we_PP found_VBD evidence_NN for_IN the_DT selection_NN of_IN additional_JJ PI_NP resistance_NN mutations_NNS ._SENT Neither_CC a_DT specific_JJ resistance_NN pattern_NN nor_CC any_DT new_JJ and_CC frequent_JJ mutation_NN could_MD be_VB inferred_VBN from_IN these_DT data_NNS ,_, which_WDT are_VBP consistent_JJ with_IN the_DT evolution_NN toward_IN high-level_JJ resistance_NN to_TO LPV_NP through_IN the_DT accumulation_NN of_IN greater_JJR numbers_NNS of_IN changes_NNS in_IN the_DT protease_NN ._SENT However_RB ,_, the_DT appearance_NN of_IN the_DT I50V_NP mutation_NN in_IN four_CD patients_NNS was_VBD of_IN particular_JJ importance_NN ,_, since_IN it_PP was_VBD recently_RB shown_VBN to_TO mediate_VB the_DT emergence_NN of_IN viruses_NNS cross-resistant_JJ to_TO both_DT LPV_NP and_CC amprenavir_NP (_( J._NP G._NP Prado_NP ,_, J._NP G._NP ,_, T._NP Wrin_NP ,_, J._NP Beauchaine_NP ,_, L._NP Ruiz_NP ,_, C._NP J._NP Petroupoulos_NP ,_, B._NP Clotet_NP ,_, R._NP D'Aquila_NP ,_, and_CC J._NP Martinez-Picado_NP ,_, Scottsdale_NP workshop_NN ,_, abstr_NN ._SENT 67_CD ,_, 2001_CD )_) ,_, precluding_VBG the_DT possibility_NN of_IN use_NN of_IN the_DT latter_JJ drug_NN in_IN patients_NNS on_IN LPV/r_NP in_IN which_WDT this_DT mutation_NN is_VBZ selected_VBN ._SENT These_DT data_NNS also_RB suggest_VBP that_IN further_JJR studies_NNS should_MD be_VB done_VBN in_IN order_NN to_TO evaluate_VB the_DT effect_NN of_IN the_DT I50V_NP mutation_NN on_IN the_DT response_NN to_TO an_DT LPV/r-containing_NP regimen_NN in_IN an_DT amprenavir-experienced_JJ population_NN ._SENT The_DT correlations_NNS between_IN pharmacokinetic_JJ parameters_NNS and_CC the_DT evolution_NN of_IN the_DT HIV-1_JJ protease_NN in_IN the_DT patients_NNS on_IN LPV/r_NP without_IN a_DT complete_JJ virological_JJ response_NN suggested_VBD that_IN low_JJ plasma_NN LPV_NP concentrations_NNS favored_VBD the_DT replication_NN of_IN unchanged_JJ PI-resistant_JJ viruses_NNS ._SENT In_IN other_JJ patients_NNS ,_, VF_NP could_MD occur_VB despite_IN normal_JJ LPV_NP concentrations_NNS ,_, with_IN the_DT selection_NN of_IN additional_JJ PI_NP resistance_NN mutations_NNS ,_, leading_VBG to_TO broader_JJR resistance_NN patterns_NNS ._SENT In_IN conclusion_NN ,_, our_PP$ results_NNS showed_VBD that_IN ,_, in_IN multiple-PI-experienced_JJ patients_NNS ,_, the_DT virological_JJ response_NN to_TO LPV/r-containing_NP salvage_NN regimens_NNS can_MD be_VB predicted_VBN by_IN the_DT LPV_NP mutation_NN score_NN ,_, even_RB if_IN specific_JJ mutations_NNS can_MD play_VB a_DT major_JJ role_NN in_IN LPV_NP resistance_NN ._SENT LPV_NP plasma_NN levels_NNS should_MD then_RB be_VB optimized_VBN by_IN using_VBG pharmacokinetics_NN measurements_NNS in_IN order_NN to_TO avoid_VB the_DT evolution_NN of_IN the_DT virus_NN toward_IN high-level_JJ resistance_NN to_TO LPV_NP and_CC to_TO other_JJ PI_NP ._SENT 